These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Introducing combined measles, mumps and rubella vaccine in Chandigarh, India: issues and concerns. Bhatnagar N; Kaur R; Gupta M; Sharma D Indian Pediatr; 2014 Jun; 51(6):441-3. PubMed ID: 24986275 [TBL] [Abstract][Full Text] [Related]
3. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS; MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231 [TBL] [Abstract][Full Text] [Related]
4. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines. Heath TC; Burgess MA; O'Brien ED Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551 [No Abstract] [Full Text] [Related]
5. Trend of measles, mumps, and rubella incidence following the measles-rubella catch up vaccination in the Republic of Korea, 2001. Choe YJ; Eom HE; Cho SI J Med Virol; 2017 Sep; 89(9):1528-1531. PubMed ID: 28303592 [TBL] [Abstract][Full Text] [Related]
6. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study. Bae GR; Choe YJ; Go UY; Kim YI; Lee JK Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654 [TBL] [Abstract][Full Text] [Related]
7. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Marin M; Broder KR; Temte JL; Snider DE; Seward JF; MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530 [TBL] [Abstract][Full Text] [Related]
8. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102 [TBL] [Abstract][Full Text] [Related]
9. MMR vaccination and disease elimination: the Finnish experience. Davidkin I; Kontio M; Paunio M; Peltola H Expert Rev Vaccines; 2010 Sep; 9(9):1045-53. PubMed ID: 20822347 [TBL] [Abstract][Full Text] [Related]
10. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine. American Academy of Pediatrics. Committee on Infectious Diseases Pediatrics; 1998 Jan; 101(1 Pt 1):129-33. PubMed ID: 11345975 [TBL] [Abstract][Full Text] [Related]
11. The impact of the media on the decision of parents in South Wales to accept measles-mumps-rubella (MMR) immunization. Walsh S; Thomas DR; Mason BW; Evans MR Epidemiol Infect; 2015 Feb; 143(3):550-60. PubMed ID: 25600667 [TBL] [Abstract][Full Text] [Related]
12. Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Vyse AJ; Gay NJ; White JM; Ramsay ME; Brown DW; Cohen BJ; Hesketh LM; Morgan-Capner P; Miller E Epidemiol Rev; 2002; 24(2):125-36. PubMed ID: 12762088 [No Abstract] [Full Text] [Related]
13. Progress toward measles and rubella elimination in Egypt. El Sayed N; Kandeel N; Barakat I; Moussa I; Alexander JP; Naouri B; Reef SE J Infect Dis; 2011 Jul; 204 Suppl 1():S318-24. PubMed ID: 21666180 [TBL] [Abstract][Full Text] [Related]
14. Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Jick H; Hagberg KW Vaccine; 2010 Jun; 28(29):4588-92. PubMed ID: 20470793 [TBL] [Abstract][Full Text] [Related]
15. Influencing factors in MMR immunisation decision making. Hill MC; Cox CL Br J Nurs; 2013 Aug 8-Sep 12; 22(15):893-8. PubMed ID: 24005660 [TBL] [Abstract][Full Text] [Related]
16. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection. Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672 [TBL] [Abstract][Full Text] [Related]
17. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278 [TBL] [Abstract][Full Text] [Related]
18. Ongoing measles and rubella transmission in Georgia, 2004-05: implications for the national and regional elimination efforts. Doshi S; Khetsuriani N; Zakhashvili K; Baidoshvili L; Imnadze P; Uzicanin A Int J Epidemiol; 2009 Feb; 38(1):182-91. PubMed ID: 19074954 [TBL] [Abstract][Full Text] [Related]
19. Toward rubella elimination in Poland: need for supplemental immunization activities, enhanced surveillance, and further integration with measles elimination efforts. Zimmerman L; Rogalska J; Wannemuehler KA; Haponiuk M; Kosek A; Pauch E; Plonska E; Veltze D; Czarkowski MP; Buddh N; Reef S; Stefanoff P J Infect Dis; 2011 Jul; 204 Suppl 1():S389-95. PubMed ID: 21666189 [TBL] [Abstract][Full Text] [Related]
20. The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study. Glasser JW; Feng Z; Omer SB; Smith PJ; Rodewald LE Lancet Infect Dis; 2016 May; 16(5):599-605. PubMed ID: 26852723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]